Lightnews — Scholar-powered news

Michael Weintraub, MD @mweintraubmd.bsky.social · 27d

We should be screening everyone with hypertension for primary aldosteronism, according to the recently released Endocrine Society guidelines.

Follow this diagnostic algorithm

Full guidelines: academic.oup.com/jcem/article...

Michael Weintraub, MD @mweintraubmd.bsky.social · Sep 19

How to individualize obesity medication treatment depending on obesity-related conditions.

Great summary by the newly released update to the AACE Evaluation and Treatment of Adults with Obesity 2025 Consensus Statement

www.endocrinepractice.org/article/S153...

Michael Weintraub, MD @mweintraubmd.bsky.social · Sep 8

Developing clinical practice guidelines is quite a process.

The GRADE format methodology translates evidence to medication decision-making recommendations after performing systemic review of the available evidence.

www.bmj.com/content/389/...

1

Michael Weintraub, MD @mweintraubmd.bsky.social · Aug 25

A higher BMI is correlated with increased risk of overall mortality. It follows the same overall curve as higher cholesterol and blood pressure, as illustrated in these graphs 📈

Controlling any and all of these risk factors lowers our overall risk of death.

pubmed.ncbi.nlm.nih.gov/28489290/

Michael Weintraub, MD @mweintraubmd.bsky.social · Aug 21

Obesity rates have skyrocketed starting in the 1970s now reaching 40% in the United States.

"It seems highly unlikely that the obesity epidemic can be explained by a widespread drop in willpower happening in the late 1970s."

www.cell.com/cell/fulltex...

Michael Weintraub, MD @mweintraubmd.bsky.social · Aug 18

A collection of all my favorite podcasts to stay up to date in Diabetes Care

Check out this Marvel-style crossover episode hosted at ADA.

overcast.fm/+AABFhuN39pM

Special Edition - ADA Scientific Sessions 2025 — Diabetes Core Update

In this special edition of Diabetes Core Update we present a special podcast recorded live at the ADA Scientific Sessions by the editors of Diabetes Core Update, Diabetes Care On Air, Diabetes Bio,…

overcast.fm

Michael Weintraub, MD @mweintraubmd.bsky.social · Jul 13

Rates of obesity of BMI 30-40 have had a mild increase over the last 20 years.

Rates of severe obesity BMI > 60 has dramatically risen- this graph is impressive.

Slide by Dr. Satya Dash at #ENDO2025

4

Michael Weintraub, MD @mweintraubmd.bsky.social · Jul 13

Pheochromocytoma survival curves are dismal, particularly in those with metastatic disease. We need better treatments for these patients.

Excellent lecture by Dr. Camilo Jimenez at #ENDO2025

3

Michael Weintraub, MD @mweintraubmd.bsky.social · Jul 12

Multiple benefits of GLP1s in reducing residual risk in those with type 1 diabetes.

Excellent talk by Dr. Kaitlin Love at #ENDO2025

4

Michael Weintraub, MD @mweintraubmd.bsky.social · Jul 12

GLP1 agonism prevents cardiovascular disease through both direct and indirect vascular effects
#ENDO2025

3

Michael Weintraub, MD @mweintraubmd.bsky.social · Jul 12

Studies showing benefits of GLP1 agonists in type 1 diabetes are accumulating.

Modest A1c reduction but impressive reductions in total daily insulin dose and weight reduction.

#ENDO2025

3

Michael Weintraub, MD @mweintraubmd.bsky.social · Jul 11

Retatrutide may be the most hotly anticipated GLP-1 based medication in development 🔥💊, but others are not far behind 🏃.

A triple agonist, UBT251, is under development in China 🇨🇳 and also mimics GLP-1, GIP, and glucagon 🧬⚗️.

1 1

Michael Weintraub, MD @mweintraubmd.bsky.social · Jul 9

“Food noise” is the “incessant mental chatter” or “constant rumination” about food.

It is increasingly recognized as a phenomenon particularly with its profound elimination with GLP1 treatment.

New Nature review: www.nature.com/articles/s41...

Great overview: conscienhealth.org/2025/07/lift...

Michael Weintraub, MD @mweintraubmd.bsky.social · Jul 5

“If you treat someone’s blood pressure or cholesterol you don’t get improvements in quality of life. You treat their weight you get all the benefits."

"That is the power of treating obesity.”

Inspiring talk by Dr. Lou Aronne on the clinical implications of CagriSema at #ADASciSessions #ADA2025

1

Michael Weintraub, MD @mweintraubmd.bsky.social · Jul 1

The long awaited triple agonist retatrutide phase 3 data is still pending ⏳🧪.

However, a body composition subanalysis of the phase 2 data is newly published 📄 showing lean mass loss of 38% of total weight loss 💪📉.

2 3

Michael Weintraub, MD @mweintraubmd.bsky.social · Jun 30

The etiology of obesity is most often multifactorial- a combination of environmental factors and genetic predisposition among thousands of genes.

However, a portion of cases are due to a single genetic cause, such as in the leptin-melanocortin pathway.

academic.oup.com/edrv/article...

Michael Weintraub, MD @mweintraubmd.bsky.social · Jun 25

What is the impact of tirzepatide on body composition? 🤔

There was an absolute loss in lean mass 💪⬇️, however there was a GREATER loss in fat mass 🧈🔥.

Thus, there was an increase in lean mass as percent body composition 📊💪. This correlates with what we see clinically

2

Reposted by Michael Weintraub, MD

Daniel Drucker @danieljdrucker.bsky.social · Jun 23

How should we think about the interesting bimagrumab & Semaglutide data #ADA2025 #weightloss #obesity How to assess meaningful functional benefit? www.statnews.com/2025/06/23/b...

Eli Lilly drug preserves lean mass in patients losing weight on Wegovy

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination therapy might change that.

www.statnews.com

1 6

Reposted by Michael Weintraub, MD

Daniel Drucker @danieljdrucker.bsky.social · Jun 23

P2 data for the once monthly GIPR Antagonist GLP-1R agonist bispecific antibody, Maritide in people with #T2D as well as in #overweight and #obesity Even data for lower dose titration over several weeks in the same paper www.nejm.org/doi/full/10....

Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial | NEJM

Maridebart cafraglutide (known as MariTide) is a long-acting peptide–antibody conjugate that combines glucagon-like peptide-1 receptor agonism and glucose-dependent insulinotropic polypeptide recep...

www.nejm.org

1 5

Michael Weintraub, MD @mweintraubmd.bsky.social · Jun 22

We’ve gone from 2 to over a dozen trials of GLP1s in alcohol use disorders in only a few years.

This comes on the heels of numerous observational and pharmacoepidiologic data supporting a reduction in alcohol use in GLP1 users.

#ADA2025 #ADASciSessions

Michael Weintraub, MD @mweintraubmd.bsky.social · Jun 22

Continuous glucose monitors are an excellent tool… when they work!

Studies report up to 26% early failure rate of these devices.

#ADA2025 #ADASciSessions

1 2

Michael Weintraub, MD @mweintraubmd.bsky.social · Jun 22

There is a national shortage of endocrinologists!

The majority of the country do not have local access to endocrinologists.

80% of those with diabetes are cared for by a PCP and no endocrinologist.

#ADA2025 #ADASciSessions

Michael Weintraub, MD @mweintraubmd.bsky.social · Jun 22

The prevalence of type 2 diabetes in the young is rising, and so are the complications.

80% of individuals develop a microvascular complication by 9 years over 9 years of follow-up!

#ADA2025 #ADASciSessions

Michael Weintraub, MD @mweintraubmd.bsky.social · Jun 22

❗ New CagriSema Phase 3 data released

Combination cagrilintide-semaglutide after 68 weeks in patients with Type 2 Diabetes and BMI > 27
⬇️ 13.7% weight loss vs 3.4% in placebo
⬇️ 1.8% a1c reduction vs 0.4% in placebo
73% had a1c <6.5%

🤢 72.5% had gastrointestinal side effects vs 34% in placebo

1

Michael Weintraub, MD @mweintraubmd.bsky.social · Jun 22

Tirzepatide in a target emulation trial demonstrates significantly lower MACE (HR 0.8) and all cause mortality (HR 0.6) compared to dulaglutide in T2DM. 🤯

#ADASciSessions #ADA2025

1 2